NEW MEDICINE, INC. – Funding Sourcing by Leaders in Pharmaceutical Business Intelligence

Funding & Deals

NEW MEDICINE, INC.
P.O. BOX 909, LAKE FOREST, CA 92609
PHONE: 1-949-830-0448 FAX: 1-949-830-0887
INFO@NEWMEDINC.COM

UPDATED on 3/25/2016

http://pharmaceuticalintelligence.com/2016/03/25/global-reach-to-the-new-website-httpwww-newmedinc-com-oncology-knowledgebase-and-future-oncology-newsletter/

New Access to and Global Reach Availability to the New website

http://www.newmedinc.com

Oncology KnowledgeBASE and
Future Oncology Newsletter

Oncology KnowledgeBASE

New Medicine’s Oncology KnowledgeBASE (nm|OK) provides a comprehensive view of the status of the global oncology drug development and personalized medicine sector in terms of:

companies developing and marketing therapeutic/in vivo imaging agents and/or in vitro diagnostics
institutions/non-profits with affiliations/agreements in this sector
therapeutic agents in development or on the market globally (over 4,500 drugs in development)
molecular targets of approved drugs and of those currently evaluated in preclinical/clinical trials or identified as playing a role in cancer
patents, orphan drug status, sales, etc.

Sample Company records >
Sample New Drug record >
Sample Marketed Drug Record >
Sample Target Record >

Quarterly Updates >

Nm|OK New Drugs and Marketed Drugs profiles >

nm|OK provides detailed profiles of over 5,000 distinct drugs/in vivo imaging agents in development and on the market by

developer/affiliate (over 1,000 pipelines)
generic name/brand name/other designation
technology/class
mechanism of action
cancer indications; over 100 indications
clinical indications; hundreds of indications
administration route
molecular target
biomarker/companion diagnostics
delivery technology
development status
clinical development by phase and status
clinical history, including trial protocols, interim and final results
sales history (when available)

nm|OK Company profiles >

nm|OK profiles over 2500 companies in the oncology space in terms of

history
management
financing
enabling technologies
affiliations/collaborations/licenses
pipelines, etc.

nm|OK Targets in Oncology Profiles >

nm|OK profiles over 1,000 molecular targets implicated in cancer and its treatment in terms of

cancer indication
utility (treatment, in vivo imaging, in vitro diagnosis, prognosis, disease monitoring
institution

News and Special Reports

Free_Icon From June 1995 to August 2008, New Medicine published Future Oncology, a comprehensive analytical newsletter tracking the evolution of global drug development in oncology. Despite of the incredible amount of effort in this area in the last 20 years, we currently face the same problems that were being tackled then, namely a lack of understanding as to the origins and mechanisms of malignancy. Despite the incredible global effort in this area and the remarkable scientific breakthroughs in biology and medicine, advanced cancer has remained an incurable disease. However, although cancer remains undefeated, treatment of this disease has created a huge global market comprised of drugs that, with few exceptions, provide marginal relief at a very high cost. Because the origins of this disease have remained obscure, there have been numerous approaches popularized at different times as to its treatment. Future Oncology has tracked these developments over time, from the rise of immunotherapy in the late 1990s to the subsequent discovery of oncogenes and tumor suppressors that shifted the emphasis from the labor intensive immunotherapy and gene transfer approaches to the relative simplicity of the production and delivery of monoclonal antibodies (MAb), oligonucleotides and small molecule drugs. Although some major advances have led to significant survival gains of patients with hematologic malignancies, they have not produced the same results in the treatment of metastatic solid tumors.

In the meantime, the competitive landscape underwent a major transformation. The archives follow the progress or demise of hundreds of commercial entities globally and hundreds of drugs, among some of the most successful to date as well some noted failures. The passage of time has produced many surprising winners and a few unexpected losers. Celgene, an unknown small company in 1995, has become a leading biotech juggernaut. Rituximab, a relatively low tech transformational therapy for the treatment of hematologic malignancies, developed by the small company Idec and approved in the USA in November 1997, may be considered the most successful anticancer agent to date both for significantly extending survival and for generating billions in sales for its developers and marketers. Since its first approval in 1995, Rituxan’s total global revenues exceeded $65 billion, including sales in the immunology sector beginning in FY 2013. Imatinib, launched in 2001, ushered the era of personalized medicine. Avastin, the first targeted treatment for solid tumors launched by Genentech in 2004, garnered over $60 billion in global revenues to date.

OLD MATERIALS, below

http://www.nmok.net

Samples of the records as they appear in the database are at http://www.nmok.net/oksite/samprecords.html

About nm/OK

New Medicine maintains nm|OK (http://www.nm|OK.net <http://www.nm%7cok.net/> ), a highly disciplined relational knowledgebase covering drug development and personalized medicine in oncology. This resource contains upward of 10,000 records of new and marketed drugs, biomarkers, imaging and in vitro diagnostics, company profiles, etc.

Development of nm|OK was initiated in 1997 and it was posted to the Internet in April 2000 as a subscription-based product mostly directed at the global business community. Over the years, almost all oncology-focused small and large companies have been subscribers to this resource.

The cancer-related sector, along with almost everything else, changed dramatically starting in 2010, mostly because of the financial crisis and the shortage of funds to support small companies lacking revenues. Slowly, industry has turned to academia to source early R&D and drug development projects and also has become globalized with participation in both R&D and marketing of drugs to diverse populations. Realizing this shift, we stopped marketing nm|OK to new clients and undertook a major improvement of the product to appeal to a wider audience of subscribers.

As you well know, the cancer field is the most complex sector in healthcare. To date, drug treatment in advanced disease may have fallen short but the science pursuing the mystery of cancer is remarkable. Over 140,000 clinical trials have been initiated and 42,000 are ongoing that are tracked by the NIH. Others are ongoing in locations that do not report to the NIH. I would venture to say that the majority of peer reviewed articles in PubMed are in some way linked to cancer. Every year thousands of talks/abstracts are presented in an endless array of meetings that are never properly evaluated, reviewed or assessed.

nm|OK presents data in this sector in an intuitive relational format that allows the users to retrieve actionable data with a few simple strokes. All relevant data is fully cited and linked to numerous sources thus presenting a complete profile of this sector from basic research to commercialization.

The opportunities of nm|OK include:

Provide a destination for all participants in the oncology field
Link press releases/articles by companies, academic institutions, foundations, etc. to the relevant nm|OK records so that the data in the articles is properly assessed and constantly updated as the records are updated
Price access to the database to avail it to non-profits as well as for-profit entities or sell advertising for free access
Provide in-depth analysis of every oncology sector with active links to the database as a premium service priced accordingly (separate security tier access currently available)

The software used in nm|OK allows graphics, images and video to be incorporated in every record thus giving suppliers the opportunity to directly describe their products to users. An Internet option also exists that would open nm|OK to outside writers/editors to act as regular contributors. Also, as a database, this resource can be recast in other formats.

There exists a remarkable opportunity to create a destination for all the needs of the oncology sector including:

basic science in mechanisms of disease, genomics
epidemiology, indications
applied R&D, preclinical studies, big data
technological advances in biologics, small molecule drugs, drug delivery, biobanking, etc.
biomarker development
in vitro tests for a variety of indications
drugs in development by originator, affiliate, mechanism, technology, clinical status, final trial results, etc.
clinical development (clinical trial protocols and results)
in vivo imaging
commercial status of approved drugs, markets, combination trials, etc.

Although an incredible amount of information is constantly pouring in from hundreds of sources in this sector, there is nothing that provides a continuous comprehensive depository of these data in a curated knowledgebase that allows those working in this field to rapidly access actionable information in their area of interest.

There is a great opportunity with a relatively small investment for this product to become a unique destination in the oncology sector on a global basis for the hundreds of thousands of company executives, academic researchers, physicians, investors, etc., participating in this area.

+++++++++++++++++++

SCROLL DOWN for URLs

The Business

a unique resource in cancer, New Medicine’s Oncology KnowledgeBASE (nm|OK) residing at http://www.nmOK.net. You probably do not remember me but I used to cover some of the early CHI meetings for our newsletter Drug and Market Development (D&MD). Since 1995, after we sold D&MD to IBC USA, we have developed and populated nm|OK, a resource tracking global drug development and personalized medicine in oncology.

Based on strict relational principles, this resource comprises over 10,000 distinct records. It tracks over 4,500 distinct therapeutic candidates profiled in great detail in terms of origin, mechanism, molecular target, preclinical evaluation and clinical trial protocols and results, companion diagnostics, enabling technologies, etc. It also profiles about 2,500 commercial entities with full company pipelines, over 1,000 molecular moieties believed to play a role in the diagnosis and treatment of this disease, and thousands of clinical trials. All relevant data is fully cited as to its origin.

Originally, this resource was developed to assist drug and biotech companies in their oncology drug development efforts. Currently, we would like to reposition it to make it available to the global oncology drug development and personalized medicine community. There are over 300,000 academic researchers and thousands of company-based employees in this field, among other professionals. We are seeking advice as how to proceed and a partner, investor or acquirer for this asset.

The opportunity is truly unique. The basic database may be available free to register users in exchange for discretely placed ads or a minimal fee, e.g. to $250 per annum. A second level of security allows for the production of highly targeted newsletters/reports in the oncology area for the commercial sector priced accordingly, e.g. $5,000 and up depending on content. Relevant data in these reports would be constantly updated via links to the basic database obviating the rapid dating of standard studies.

The Assets (Inventory)

New Medicine’s Oncology KnowledgeBASE (nm|OK) is a highly disciplined relational database covering global drug development and personalized medicine in oncology.

The the complete list of assets directly related to nm|OK are:  Nm|OK

 · An Internet version (http://www.nmok.net <http://www.nmok.net> ) that resides on a server managed by Andornot (http://www.andornot.com), a Canadian reseller of software originally developed and marketed by InMagic (http://www.inmagic.com) that was recently purchased by Lucidea (http://www.lucidea.com). The server is dedicated to working with this software and the staff is trained to troubleshoot the product and program/update the software. The program used is referred to as WebPublisher and its set up and contents can only be modified by the administrator at New Medicine or Andornot.

· An intranet version, DBText, residing in our server that we use to enter all information to be uploaded periodically to the Internet version The use of an Intranet version provide the editor considerable flexibility in managing/editing and reviewing entries before they are published to the Net. However, a version of the software called Presto, allows the use of an Internet site alone and also allows others with the appropriate credentials to upload data to the database.  Future Oncology

 Future Oncology (ISSN 1082-331X), first published in hard copy in June 1995, is an analytical newsletter in the oncology sector. Contents of past issues provided as hard copy, are http://www.newmedinc.com/futonc/contents_date.html. All past issues are available as PDF.    URL

www.nmok.net, November 2016

www.oncologyknowledgebase.com, May 2015

www.futureoncology.com, May 2015

www.futureaging.com, May 2015

www.oncologyknowledgebase.net

www.futurecardiology.com

www.futureimmunology.com

Mailing Lists

We have a 3,000 name mailing list of company executives, which is updated every 6 months. We also have a list of editors of various publications in the healthcare field.   *About Lucidea

Lucidea is a knowledge management software company, helping people navigate the ever-expanding universe of information, turning it into actionable knowledge by providing tools that accelerate access to knowledge resources, while simplifying their management. For further information about Lucidea’s knowledge management, museums, archives, legal portal or cost recovery products, call (604) 278-6717, email sales@lucidea.com, or visit http://www.lucidea.com <http://www.lucidea.com>.

About nm|OK

 New Medicine’s Oncology KnowledgeBASE (nm|OK) is a highly disciplined relational database designed to provide a comprehensive view of all aspects of the global oncology sector allowing the user to retrieve comprehensive data along numerous lines of inquiry. Numerous sources (http://www.nmok.net/oksite/sources.html) are interrogated to build the records of nm|OK and all data is cited with links to the origin of the data when appropriate.    Without belaboring the point, cancer is undeniably the most complex of all healthcare sectors and keeping up with developments in this field is extremely challenging. Given the incredible volume of information in oncology coming from numerous sources one would ask why is a resource like nm|OK necessary. Although tons of data is available from many sources, in each case they only cover a narrow miniscule aspect of the sector without placing the information in context.    nm|OK consists of 7 modules, Company, New Drugs, Marketed Drugs, Targets, Combination Trials, News and Glossary. The largest module is the New Drugs module that contains over 4,500 novel drugs that have not been approved for any indication.

The Company module profiles over 2,500 entities by describing their operations, drug development and drug delivery technologies, and their products and services in personalized medicine, including hundreds of products (screening tests, diagnostics, pharmacogenomics, prognostics, disease monitoring tests, theragnostics, etc.) in the in vitro testing (IVT) area in oncology. nm|OK describes hundreds of technology platforms used to discover, evaluate, optimize, and/or deliver anticancer agents. See sample records at  The New Drugs module profiles over 4,500 novel anticancer agents in development such as cytotoxics; synthetic nucleic acid sequences (oligonucleotides, RNAi, etc.); small molecule drugs; biologics (monoclonal antibodies, fusion proteins, antibody-drug conjugates); immunotherapeutics; oncolytics; etc. These agents address over 100 cancer types and 2,000 to 3,000 clinical indications.

Data incorporated in these profiles include preclinical studies, detailed trial protocols. In addition, the record identifies the primary developer and affiliated partners involved with the origin, preclinical and clinical development of the agent. This module also describes in vivo imaging agents and drugs addressing the complications of cancer and its treatment. Overall, the New Drugs module includes about 850 company pipelines in cancer. See sample record at  The Marketed Drugs module profiles drugs approved for the treatment of cancer and complications arising from cancer and its treatment.    The Targets module profiles over 1.000 molecular markers linked to carcinogenesis, cancer progression/metastases, treatment resistance, etc. The module also describes academic efforts to develop in vitro tests and therapeutics based on these targets.

About Cancer

Every year, an estimated 14.1 million people are diagnosed with cancer and about 8 million die from the disease worldwide and the global number of cancer deaths is projected to increase.

The Global Cancer Pharmaceutical and the Personalized Oncology Sector

Pharmaceuticals

 According to IMS (http://www.theimsinstitute.org) the global market for oncology drugs, including those used in supportive care, reached $91 billion in 2013 as measured at ex-manufacturer prices and not reflecting off-invoice discounts and rebates, compared with $71 billion in 2008 and $37 billion a decade ago. The USA market for oncology drugs was $37 billion (41%) in 2013.

Cancer accounts for more than 30% of all pharmaceuticals in preclinical and phase I clinical development; 22 new molecular entities were launched 2012 and 2013. In 2011 there were 948 oncology drugs in development compared to 252 in cardiovascular disease, 212 in diabetes, and 460 in all rare diseases combined. Because newly launched treatments typically bring only between 2 and 6 months of incremental overall survival, novel approaches in development have accelerated in search of better efficacies. Biologicals account for about 40% of the global market. Therefore, the specter of the advent of biosimilars and biobetters are spurring research in this sector for improved versions of drugs whose patents are expiring.

There are at least 1,000 private/public companies developing/commercializing pharmaceuticals in the major markets of the USA, Canada, Europe, Japan and Oceania; many also operate in Asia, Africa and Latin America.

In vitro Diagnostics (IVT)

In addition, the global diagnostics market is expected to grow from about $2 billion in 2013 to over $3.5 billion in 2015.

There are at least 380 private/public companies developing/commercializing oncology-related IVT in the major markets of the USA, Canada, Europe, Japan and Oceania; others operate in Asia, Africa and Latin America.

There are over 750 markers linked to malignancy with new ones being discovered on a daily basis. In addition, there are mutations, single nucleotide polymorphisms (SNP), variants, fusions, epigenetic modifications, etc. Each of these effectors would eventually would need to be detected by an IVT to guide patient selection and treatment choice.

Currently there are hundreds of tests, many referred to as companion diagnostics as they are used to select patients for treatment by a particular agent.

Positioning nm|OK

 To date, nm|OK has only been available by a paid annual subscription targeting the commercial sector almost exclusively, although periodically hospitals, foundations and government agencies also subscribed.

The database has two levels of security, one to access the database and another to access special items. Everything placed in the second level of security is readily linked to all relevant items in the main database.

In 2011, we decided to reposition the database as a destination for the global oncology community. This can be accomplished by: · charging a very small annual fee ($200-$250) per user (with a consideration for IP access for major institutions) or  · requiring free registration and incorporating ads   The ad option presents a unique opportunity for this resource. The ads would be totally nonintrusive, no flashing, bobbing, streaming stuff. Companies would be given the opportunity to post links on their company page to posters, webcasts, product introductions, licensing opportunities, etc. When a user goes to the company’s page he would be given the chance to click in any of those to see more. They can be very subtle, just a description of the item with the link. Similarly, companies can do the same thing on the product records regarding new developments such as abstracts, new trials, etc.

The current second level of security (now the first level) would incorporate all kinds of enhanced products, such as news releases, university/government licensing opportunities, and various news reports. This may be priced at an annual fee of $250.

The second level of security may house Future Oncology (12 issues) covering major aspects of the field, written by experts. This access can be priced at $12,000 and up and geared to commercial clients.

Opportunities for nm|OK

 Researchers (Academic and Industrial) The oncology sector dominates the global R&D and clinical development effort. Over 50,000 academics in the USA are working in the life sciences field and most are in some way involved in cancer. In addition, thousands are working in industry. Similarly, academics in every major country in the world are working in the cancer area. A cursory review of PubMed (http://www.ncbi.nlm.nih.gov/pubmed), the depository of all peer reviewed journal articles originating around the world, readily informs that the largest share of the publications relate to oncology issues with many coming from abroad, particularly China.

Oncologists About 14,000 oncologists practice in the USA and thousands more globally

Others Hospitals Clinical Research Organizations (CRO) Foundations Biobanks Government regulatory agencies Government Institutes Enabling technology companies (big data, sequencing, product development, preclinical development) Investors (venture funds, Wall Street firms, etc.)

This page has the following sub pages.